An in vitro approach for prioritization and evaluation of chemical effects on glucocorticoid receptor mediated adipogenesis

ABSTRACT Rising obesity rates worldwide have socio‐economic ramifications. While genetics, diet, and lack of exercise are major contributors to obesity, environmental factors may enhance susceptibility through disruption of hormone homeostasis and metabolic processes. The obesogen hypothesis contends that chemical exposure early in development may enhance adipocyte differentiation, thereby increasing the number of adipocytes and predisposing for obesity and metabolic disease. We previously developed a primary human adipose stem cell (hASC) assay to evaluate the effect of environmental chemicals on PPARG‐dependent adipogenesis. Here, the assay was modified to determine the effects of chemicals on the glucocorticoid receptor (GR) pathway. In differentiation cocktail lacking the glucocorticoid agonist dexamethasone (DEX), hASCs do not differentiate into adipocytes. In the presence of GR agonists, adipocyte maturation was observed using phenotypic makers for lipid accumulation, adipokine secretion, and expression of key genes. To evaluate the role of environmental compounds on adipocyte differentiation, progenitor cells were treated with 19 prioritized compounds previously identified by ToxPi as having GR‐dependent bioactivity, and multiplexed assays were used to confirm a GR‐dependent mode of action. Five chemicals were found to be strong agonists. The assay was also modified to evaluate GR‐antagonists, and 8/10 of the hypothesized antagonists inhibited adipogenesis. The in vitro bioactivity data was put into context with extrapolated human steady state concentrations (Css) and clinical exposure data (Cmax). These data support using a human adipose‐derived stem cell differentiation assay to test the potential of chemicals to alter human GR‐dependent adipogenesis. HIGHLIGHTSA biological pathway approach to testing chemicals for GR‐dependent adipogenesisToxCast GR assays were used to prioritize chemicals for phenotypic in vitro testing.Fit‐for‐purpose assays can be used for comparing in vitro potency to human exposure.Testing prioritized chemicals in vitro can help provide context for human risk.

[1]  Bruce Blumberg,et al.  Environmental obesogens: organotins and endocrine disruption via nuclear receptor signaling. , 2006, Endocrinology.

[2]  J. Wagner,et al.  Comparative bioavailability: Eight commercial prednisone tablets , 1976, Journal of Pharmacokinetics and Biopharmaceutics.

[3]  H. Kwon,et al.  Adipokines Mediate Inflammation and Insulin Resistance , 2013, Front. Endocrinol..

[4]  R. Endele,et al.  Kinetics of canrenone after single and multiple doses of spironolactone , 1979, European Journal of Clinical Pharmacology.

[5]  R. Stephany.  Hormonal growth promoting agents in food producing animals. , 2010, Handbook of experimental pharmacology.

[6]  A. Kelly,et al.  Review of Childhood Obesity: From Epidemiology, Etiology, and Comorbidities to Clinical Assessment and Treatment , 2017, Mayo Clinic proceedings.

[7]  M. Brady,et al.  The endocrine disrupting chemical tolylfluanid alters adipocyte metabolism via glucocorticoid receptor activation. , 2013, Molecular endocrinology.

[8]  P. Beaune,et al.  Xenobiotic-Metabolizing Cytochromes P450 in Human White Adipose Tissue: Expression and Induction , 2010, Drug Metabolism and Disposition.

[9]  R. Moore,et al.  Disposition of synthetic glucocorticoids I. Pharmacokinetics of dexamethasone in healthy adults , 1979, Journal of Pharmacokinetics and Biopharmaceutics.

[10]  H. Möllmann,et al.  Pharmacokinetics of Triamcinolone Acetonide After Intravenous, Oral, and Inhaled Administration , 1995, Journal of clinical pharmacology.

[11]  M. Brady,et al.  Environmental Endocrine Disruptors Promote Adipogenesis in the 3T3‐L1 Cell Line through Glucocorticoid Receptor Activation , 2010, Obesity.

[12]  Michael A. Gallo,et al.  Role of Environmental Chemicals in Diabetes and Obesity: A National Toxicology Program Workshop Review , 2012, Environmental health perspectives.

[13]  FoleyBriana,et al.  Development of a Human Adipose-Derived Stem Cell Model for Characterization of Chemical Modulation of Adipogenesis , 2015 .

[14]  B. Jang,et al.  Anti-Adipogenic Effects on 3T3-L1 Cells and Zebrafish by Tanshinone IIA , 2017, International journal of molecular sciences.

[15]  P. Stewart,et al.  11β-Hydroxysteroid dehydrogenase and the pre-receptor regulation of corticosteroid hormone action , 2005 .

[16]  C. McCormick,et al.  Translational relevance of rodent models of hypothalamic-pituitary-adrenal function and stressors in adolescence , 2016, Neurobiology of Stress.

[17]  M. Cooper,et al.  The 11beta-hydroxysteroid dehydrogenase enzymes--arbiters of the effects of glucocorticoids in synovium and bone. , 2010, Rheumatology.

[18]  M. Milani,et al.  Comparison of different preparation methods of biological samples for FIB milling and SEM investigation , 2009, Journal of microscopy.

[19]  J. Sugatani,et al.  Expression and Induction of Cytochromes P450 in Rat White Adipose Tissue , 2004, Journal of Pharmacology and Experimental Therapeutics.

[20]  D. Draganov.  Human PON3, effects beyond the HDL: clues from human PON3 transgenic mice. , 2007, Circulation research.

[21]  David M. Reif,et al.  Test driving ToxCast: endocrine profiling for 1858 chemicals included in phase II. , 2014, Current opinion in pharmacology.

[22]  H. Möllmann,et al.  Pharmacokinetics of triamcinolone acetonide and its phosphate ester , 2004, European Journal of Clinical Pharmacology.

[23]  Travis E. Oliphant,et al.  Python for Scientific Computing , 2007, Computing in Science & Engineering.

[24]  Shuji Ohno,et al.  Determination of mRNA Expression of Human UDP-Glucuronosyltransferases and Application for Localization in Various Human Tissues by Real-Time Reverse Transcriptase-Polymerase Chain Reaction , 2009, Drug Metabolism and Disposition.

[25]  A. Gil,et al.  Cell Models and Their Application for Studying Adipogenic Differentiation in Relation to Obesity: A Review , 2016, International journal of molecular sciences.

[26]  Teresa Oliveira,et al.  Biochemistry of adipose tissue: an endocrine organ , 2013, Archives of medical science : AMS.

[27]  J. Seckl,et al.  Proinflammatory cytokine induction of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) in human adipocytes is mediated by MEK, C/EBPβ, and NF-κB/RelA. , 2014, The Journal of clinical endocrinology and metabolism.

[28]  S. Farmer.  Transcriptional control of adipocyte formation. , 2006, Cell metabolism.

[29]  Miguel M Santos,et al.  The Mammalian “Obesogen” Tributyltin Targets Hepatic Triglyceride Accumulation and the Transcriptional Regulation of Lipid Metabolism in the Liver and Brain of Zebrafish , 2015, PloS one.

[30]  F. Stanczyk.  All progestins are not created equal , 2003, Steroids.

[31]  S. Griffith,et al.  Effect of zonisamide on the pharmacokinetics and pharmacodynamics of a combination ethinyl estradiol-norethindrone oral contraceptive in healthy women. , 2004, Clinical therapeutics.

[32]  L. Giudice,et al.  Endocrine-disrupting chemicals: an Endocrine Society scientific statement. , 2009, Endocrine reviews.

[33]  Tom Britton,et al.  Dynamics of fat cell turnover in humans , 2008, Nature.

[34]  Ruili Huang,et al.  Predictive endocrine testing in the 21st century using in vitro assays of estrogen receptor signaling responses. , 2014, Environmental science & technology.

[35]  M. Dolenc,et al.  Comparison of in vitro hormone activities of novel flame retardants TBB, TBPH and their metabolites TBBA and TBMEPH using reporter gene assays. , 2016, Chemosphere.

[36]  D. Philibert,et al.  RU 38486: a potent antiglucocorticoid in vitro and in vivo. , 1985, Journal of steroid biochemistry.

[37]  R. Judson,et al.  High throughput heuristics for prioritizing human exposure to environmental chemicals. , 2014, Environmental science & technology.

[38]  E. Atlas,et al.  Firemaster® 550 and its components isopropylated triphenyl phosphate and triphenyl phosphate enhance adipogenesis and transcriptional activity of peroxisome proliferator activated receptor (Pparγ) on the adipocyte protein 2 (aP2) promoter , 2017, PloS one.

[39]  M. J. den Broeder,et al.  Altered Adipogenesis in Zebrafish Larvae Following High Fat Diet and Chemical Exposure Is Visualised by Stimulated Raman Scattering Microscopy , 2017, International journal of molecular sciences.

[40]  L. Ma,et al.  Effects of novel brominated flame retardant TBPH and its metabolite TBMEHP on human vascular endothelial cells: Implication for human health risks , 2017, Environmental research.

[41]  Participants,et al.  Moving Beyond Prioritization Toward True In Vitro Safety Assessment , 2016 .

[42]  Harvey J Clewell,et al.  Evaluating opportunities for advancing the use of alternative methods in risk assessment through the development of fit-for-purpose in vitro assays. , 2018, Toxicology in vitro : an international journal published in association with BIBRA.

[43]  F. Malone,et al.  Pharmacokinetics of 17-hydroxyprogesterone caproate in multifetal gestation. , 2011, American journal of obstetrics and gynecology.

[44]  M. Symonds.  Adipose Tissue Biology , 2012, Springer New York.

[45]  B. Walker,et al.  Glucocorticoids and 11beta-hydroxysteroid dehydrogenase in adipose tissue. , 2004, Recent progress in hormone research.

[46]  D. Argenti,et al.  A Pharmacokinetic Study to Evaluate the Absolute Bioavailability of Triamcinolone Acetonide following Inhalation Administration , 1999, Journal of clinical pharmacology.

[47]  O. Heikinheimo,et al.  Pharmacokinetics of mifepristone after low oral doses. , 1996, Contraception.

[48]  F. Vallée,et al.  Effects of Rifabutin and Rifampicin on the Pharmacokinetics of Ethinylestradiol and Norethindrone , 1998, Journal of clinical pharmacology.

[49]  David M. Reif,et al.  Endocrine Profiling and Prioritization of Environmental Chemicals Using ToxCast Data , 2010, Environmental health perspectives.

[50]  Ruili Huang,et al.  Integrated Model of Chemical Perturbations of a Biological Pathway Using 18 In Vitro High-Throughput Screening Assays for the Estrogen Receptor. , 2015, Toxicological sciences : an official journal of the Society of Toxicology.

[51]  Bas J Blaauboer,et al.  Evaluation of simple in vitro to in vivo extrapolation approaches for environmental compounds. , 2014, Toxicology in vitro : an international journal published in association with BIBRA.

[52]  T. Staks,et al.  Pharmacokinetics of cyproterone acetate and ethinylestradiol in 15 women who received a combination oral contraceptive during three treatment cycles. , 1993, Contraception.

[53]  P. Neuvonen,et al.  The cytochrome P450 3A4 inhibitor itraconazole markedly increases the plasma concentrations of dexamethasone and enhances its adrenal‐suppressant effect , 2000, Clinical pharmacology and therapeutics.

[54]  A. Regassa,et al.  Molecular Regulation of Adipogenesis and Potential Anti-Adipogenic Bioactive Molecules , 2016, International journal of molecular sciences.

[55]  Jeremy W Tomlinson,et al.  Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 activity in vivo limits glucocorticoid exposure to human adipose tissue and decreases lipolysis. , 2007, The Journal of clinical endocrinology and metabolism.

[56]  W. Summerskill,et al.  Prednisone for chronic active liver disease: pharmacokinetics, including conversion to prednisolone. , 1977, Gastroenterology.

[57]  W. Kuhnz,et al.  PHARMACOKINETICS AND DISPOSITION , 1997 .

[58]  E. Graul,et al.  Dose-dependent pharmacokinetics of dexamethasone , 2004, European Journal of Clinical Pharmacology.

[59]  Melvin E. Andersen,et al.  Editor’s Highlight: Screening ToxCast Prioritized Chemicals for PPARG Function in a Human Adipose-Derived Stem Cell Model of Adipogenesis , 2016, Toxicological sciences : an official journal of the Society of Toxicology.

[60]  O. Heikinheimo.  Clinical Pharmacokinetics of Mifepristone , 1997, Clinical pharmacokinetics.

[61]  N. Sarkar.  Mifepristone: bioavailability, pharmacokinetics and use-effectiveness. , 2002, European journal of obstetrics, gynecology, and reproductive biology.